Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years. Despite some toxicities, it has demonstrated significant efficacy in elderly patients, as well as in the setting of younger subjects receiving autologous stem cell transplantation. Here, we report and discuss the clinical results achieved with thalidomide alone or in combination with dexamethasone or other drugs, such as melphalan, cyclophosphamide, doxorubicin and bortezomib, in previously untreated myeloma patients.
Role of thalidomide in previously untreated patients with multiple myeloma / Musto, P; D'Auria, F; Pietrantuono, G; Bringhen, S; Morabito, F; Di Raimondo, F; Pozzi, Samantha; Sacchi, Stefano; Boccadoro, M; Palumbo, A.. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - STAMPA. - 8:10(2008), pp. 1569-1580. [10.1586/14737140.8.10.1569]
Role of thalidomide in previously untreated patients with multiple myeloma
POZZI, Samantha;SACCHI, Stefano;
2008
Abstract
Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years. Despite some toxicities, it has demonstrated significant efficacy in elderly patients, as well as in the setting of younger subjects receiving autologous stem cell transplantation. Here, we report and discuss the clinical results achieved with thalidomide alone or in combination with dexamethasone or other drugs, such as melphalan, cyclophosphamide, doxorubicin and bortezomib, in previously untreated myeloma patients.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
